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Abstract 
Hyperinsulinemic hypoglycemia (HI) and congenital polycystic kidney disease 
(PKD) are rare, genetically heterogeneous disorders. The co-occurrence 
(HIPKD) in 17 children from 11 unrelated families suggested the existence of a 
previously unrecognized genetic disorder. Whole genome linkage analysis in 5 
informative families identified a single significant (LOD 6.5) locus on 
chromosome 16p13.2. Sequencing of the coding regions of all linked genes 
failed to identify biallelic mutations. Instead, a promoter mutation (c.-167G>T) 
in PMM2 was found in all patients, either homozygous or in trans with PMM2 
coding mutations. PMM2 encodes a key enzyme in N-glycosylation. Abnormal 
glycosylation has previously been associated with polycystic kidney disease 
and we show that deglycosylation in pancreatic β-cells alters insulin secretion. 
Recessive coding mutations in PMM2 cause congenital disorder of 
glycosylation type 1a (CDG1A), a devastating multi-system disorder with 
prominent neurological involvement. Yet the typical clinical features of CDG1A 
were absent in our patients and the diagnostic test of transferrin isoelectric 
focusing was normal, clearly separating HIPKD from CDG1A and establishing 
PMM2 pleiotropy. The promoter mutation showed decreased transcriptional 
activity in patient kidney cells and impaired binding of the transcription factor 
ZNF143. In silico analysis suggests an important role of ZNF143 for the 
formation of a chromatin loop including PMM2. 
We propose that the promoter mutation alters tissue-specific chromatin loop 
formation with consequent organ-specific deficiency of PMM2 leading to the 
restricted phenotype of HIPKD. Our findings extend the spectrum of genetic 
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causes for both HI and PKD and provide insights into gene regulation and 
PMM2 pleiotropy.  
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Introduction 
Autosomal recessive polycystic kidney disease (ARPKD), a rare disorder with 
an estimated incidence of 1:20000 live births, is characterized by the 
combination of polycystic kidneys and hepatic fibrosis.1 It is caused by 
mutations in PKHD1, although mutations in other ciliary disease genes may 
phenocopy the disorder.2, 3 Causative mutations are identified in approximately 
85% of cases.4 Here we investigated patients with an ARPKD-like clinical 
presentation that were genetically unsolved and prominently characterized by a 
concurrent clinical diagnosis of hyperinsulinemic hypoglycemia (HI). HI in itself 
is also a rare disorder with an estimated incidence of 1:50000 and most 
commonly associated with mutations in the ABCC8 and KCNJ11 genes 
involved in the regulation of insulin release from pancreatic β-cells.5, 6 
However, no causative mutations had been identified in these genes in any of 
the patients described here. 
The co-occurrence of these two rare disorders in multiple patients and without 
identified mutations in known disease genes strongly suggested the existence 
of a yet undescribed Mendelian disorder with recessive inheritance.  
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Results 
Patients 
We noted the co-occurrence of the clinical diagnoses of HI and 
polycystic kidney disease (HIPKD) in 17 patients from 11 families of European 
descent (Table 1 and Supplemental Figure 1), including a consanguineous 
family with 4 affected individuals. Multiple siblings were affected in 3 further 
pedigrees, consistent with autosomal recessive inheritance (Figure 1 and 
Supplemental Figure 1).  
Eight patients from 7 families had been referred for genetic testing for 
hyperinsulinemic hypoglycemia (HI) through an international study of 1250 
families. All patients had been tested for ABCC8 and KCNJ11 mutations, which 
are the most common cause of HI, yet none were found. Mutations in PKHD1, 
the causative gene for ARPKD, had been excluded by linkage and/or 
sequencing analysis in 14 patients. 
 
Kidney disease 
All patients were found to have enlarged kidneys with multiple cysts on 
imaging, prompting an initial clinical diagnosis of ARPKD (Figure 2). Severity of 
kidney disease was variable: 3 patients presented antenatally, in others kidney 
cysts were discovered incidentally during childhood. Blood tests were 
consistent with chronic kidney disease (CKD) stage 1 or 2 in 9 patients, 
whereas 2 patients (1.1, and 6.1, see Table 1) progressed to end-stage kidney 
disease (ESKD) at age 20 and 2 years, respectively with need for dialysis or 
transplantation. Native kidneys were removed at the time of transplant in 
patient 6.1 due to their massive size (20 cm longitudinal diameter, normal <7.7) 
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and histology was consistent with a predominantly glomerulocystic disorder 
(Figure 2).  
 
Liver disease 
In addition, liver cysts were seen in 8 patients. Other patients had no 
abnormalities on liver imaging (Table 1), including patient 8.1, whose liver 
biopsy (age 1 year) showed ductal plate malformation (Figure 3). Liver function 
tests were normal or only borderline elevated. 
 
Hyperinsulinemic hypoglycemia 
HI was diagnosed at a median age of 10 months of life, often presenting 
with hypoglycemic seizures. The spectrum of severity varied and in one patient 
(1.3) diagnosis of HI was made only at 4 years of age. Most were treated with 
diazoxide and responded to this therapy, although some patients did not 
receive any treatment. 
 
Other organs 
No manifestations in other organs or dysmorphologies were noted. 
Specifically, there was no evidence for neurological impairment. Patients 2.1, 
2.2 and 6.1 underwent detailed audiological and ophthalmological testing 
including electroretinogram, which revealed no abnormalities. 
Serum transferrin glycosylation was assessed by isoelectric focusing in 
11 patients and was normal in all, excluding a substantial global defect in 
glycosylation. 
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Genetic analysis 
Autozygosity analysis of SNP-chip genotype data in the 
consanguineous family revealed a homozygous 2.5Mb region on chromosome 
16p13.2. Whole genome multipoint parametric linkage analysis in this and 4 
other informative families confirmed and refined this to a single significant 
locus of 2.3 Mb including 14 annotated genes on chromosome 16p.13.2 with a 
combined LOD score of 6.5 (Figure 1). 
Using next generation sequencing, we identified a non-coding variant in 
the promoter region for PMM2 (encoding Phosphomannomutase 2, a key 
enzyme in N-glycosylation), c.-167G>T, not previously documented in 
databases (Figure 1). Sanger sequencing confirmed the presence of this 
mutation in all patients. It was found in homozygous state in the 4 patients from 
the consanguineous family and in compound heterozygote state with 
previously described deleterious coding mutations in PMM2 in all others (Table 
1). Sequencing of the parents from families 2-11 confirmed that these 
mutations were inherited in trans. 
 
Functional studies of the promoter variant  
The identified c.-167G>T mutation lies in a region previously described 
as a promoter of PMM2.7 We assessed the effect of the promoter variant on 
PMM2 transcription in vitro, using human kidney and pancreatic β-cell lines. 
Cells were transfected with luciferase under the control of either wild type or 
mutant promoter. In both cell models, the promoter variant caused a significant 
reduction in luciferase activity (Figure 4A,B). We also assessed PMM2 
transcription in kidney cells derived from the nephrectomy from patient 6.1, 
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compound heterozygous for the promoter mutation c.-167G>T and the 
missense mutation c.422G>A; p.R141H. Digital quantitative PCR revealed 
reduced expression of the allele containing the promoter variant compared to 
the other allele (Figure 4C). The promoter mutation lies in a recognized binding 
site for the transcription factor ZNF143.7 We therefore assessed binding of 
ZNF143 to the promoter using an Electrophoretic Mobility Shift Assay (EMSA), 
which demonstrated significantly reduced binding to the mutant promoter 
compared to wild type (Figure 4D,E). 
To assess the consequences of decreased PMM2 activity on insulin 
secretion, we investigated the effect of deglycosylation in a murine pancreatic 
β-cell line.8 We noted a significant increase in insulin secretion after stimulation 
with the protein kinase C activator, phorbol-12 myristate-13 acetate (Figure 
4F), establishing a direct link between glycosylation and insulin secretion. 
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Discussion 
 
HIPKD:  a disorder with pancreatic, kidney and liver manifestations 
We describe a previously unreported disorder presenting with ARPKD-
like kidney disease and HI in childhood.  
Most patients presented with hypoglycemia in the first year of life, 
consistent with congenital HI. Hypoglycemia was the first recognized 
manifestation of HIPKD in most patients, typically presenting with seizures. 
However, severity varied with delayed diagnosis in some.  
All patients had enlarged cystic kidneys, which typically led to an initial 
diagnosis of ARPKD. Yet, kidney manifestations of HIPKD differ from ARPKD. 
Histology of the kidneys from patient 6.1 shows predominantly, if not 
exclusively glomerular cysts, whereas in ARPKD cysts arise from fusiform 
dilatation of the collecting duct.3 Several of the patients had renal cysts seen 
on antenatal ultrasound, yet none had severe manifestations with 
oligohydramnios and consequent complications, such as pulmonary 
hypoplasia. Instead, 2 patients (1.1 and 6.1), including the one with the earliest 
progression to ESKD (age 2 years), had antenatal documentation of 
polyhydramnios. In contrast, about 30-40% of patients with ARPKD die in the 
neonatal period from complications of oligohydramnios.4  
Liver involvement is an obligate aspect of ARPKD and the presence of 
liver manifestations initially seemed to support a diagnosis of ARPKD in our 
patients. Liver abnormalities on imaging were noted in 8 patients, mostly 
showing scattered cysts and/or a heterogeneous echotexture. Liver enzyme 
levels in plasma were normal or only borderline abnormal. Interestingly, liver 
imaging was normal in patient 8.1, who underwent a liver biopsy to establish a 
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diagnosis, which showed ductal plate malformation (Figure 3). This is the only 
patient in our cohort who had a liver biopsy and it suggests that the absence of 
abnormalities on imaging or blood tests does not exclude the possibility of 
microscopic structural changes in the liver of patients with HIPKD. None of the 
patients reported here had evidence of portal hypertension, a complication 
seen in about a quarter of patients with ARPKD.9 
 
HIPKD and the promoter mutation  
The identification of a promoter mutation in PMM2 was unexpected, as 
there was no evidence for a systemic disorder of glycosylation in our patients. 
Autosomal recessive mutations in PMM2 are the cause of a devastating 
multisystemic disease called congenital disorder of glycosylation 1a (CDG1A). 
Neurological problems usually predominate the phenotype of CDG1A, with 
affected patients presenting with severe developmental delay, strabism and 
muscular hypotonia, none of which was noted in our patients. Moreover, typical 
dysmorphic features of CDG1A, such as protruding ears, inverted nipples and 
abnormal subcutaneous fat pads were not seen in any of our HIPKD patients. 
Infantile demise is common.10 Later on, in surviving patients, other 
complications, such as thrombotic events, skeletal deformities, epilepsy, 
retinitis pigmentosa, hypogonadism and peripheral neuropathy become 
apparent.11 None of our patients presented any evidence for such involvement, 
clearly distinguishing HIPKD from CDG1A.  
A key diagnostic feature of CDG1A is the presence of specific 
abnormalities seen with isoelectric focusing of transferrin due to abnormal 
glycosylation. Importantly, this test was normal in all HIPKD patients tested. 
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While normal, or only slightly abnormal transferrin isoelectric patterns have 
been reported in a few patients with a mild form of CDG1A with isolated mild 
neurological and no visceral involvement, this is clearly clinically distinct from 
HIPKD patients.12, 13 
The phenotype of HIPKD appears to be restricted to kidneys and 
pancreatic β-cells with additional liver involvement, which is distinct from 
CDG1A, where visceral involvement is only noted in the severe early-onset 
form with neurological and dysmorphic manifestations. A potential explanation 
for this organ-specific involvement would be a unique sensitivity of kidney, 
pancreas and liver to impaired PMM2 function. Under this hypothesis, the 
promoter mutation would affect PMM2 function to just such a degree, that only 
kidney, pancreatic β-cells and liver are affected, whereas PMM2 activity was 
still sufficient to avoid manifestations in other organs. However, this is not 
consistent with observations in patients with CDG1A, as those with mild forms 
show isolated neurological involvement only.12, 13 This strongly suggests that 
the brain is most sensitive to loss of PMM2 function and mild impairment thus 
primarily causes neurological problems. The severity of manifestations seen in 
HIPKD patients in the three key organ systems involved, yet with no evidence 
of systemic involvement clearly argues for a tissue-specific effect of the 
promoter mutation. While specific neurological investigations, such as an MRI 
scan of the brain have not been performed due to a lack of clinical indication, 
previous reports of CDG1A patients with visceral manifestations as seen in 
HIPKD also had associated debilitating neurological and dysmorphic features, 
which are absent in HIPKD. 
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Mutations affecting PMM2 function or transcription can therefore cause 
either CDG1A or HIPKD and such pleiotropy is well recognized: mutations in 
TRPV4, for instance, are associated with at least 8 different disorders, 
comprising such divergent clinical phenotypes as skeletal dysplasias or motor 
and sensory neuropathies.14 Mutations in OCRL cause either the systemic 
disorder Lowe syndrome or the kidney-specific Dent disease.15 Yet, while the 
pleiotropic effects of most of these genes are poorly understood, our data here 
clearly point to tissue-specific dysregulation of PMM2 by the promoter mutation 
as the key disease mechanism in HIPKD. Indeed, it has been suggested that 
altered chromatin looping allows for tissue-specific interactions between 
enhancers and promoters, thus constituting a key mechanism for genetic 
pleiotropy.16 Our promoter mutation appears to confirm this concept. 
 
Promoter mutation and chromatin loops 
Gene expression can be modulated by regulatory regions many 
megabases away from the coding region and it is the three-dimensional 
architecture of chromatin that is critical to allow this interaction.17 This involves 
the formation of structural chromatin “loops”, typically between 40 kb and 3 Mb 
in size and flanked by binding sites for CCCTC-binding factor (CTCF) in 
convergent orientation.17 These loops, also called “topologically associated 
domains (TAD), serve as fundamental regulatory units of transcription.18 
Inspection of publicly available data for transcription factor binding and 
chromatin interactions shows that the region around PMM2 contains a number 
of CTCF sites and functional promoters (Supplemental Figure 2). Interaction 
between pairs of CTCF sites has been observed in a variety of combinations, 
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potentially dynamic and tissue specific in nature, to form localized chromatin 
loops. Moreover, these data suggest an interaction between ZNF143 and 
specific CTCF sites, consistent with previous observations of functional 
interactions between these two DNA binding proteins, which affect the three-
dimensional structure of such chromatin loops by linking CTCF with distal 
regulatory elements, facilitating specific gene regulation.19-21 Here, ZNF143 
binds to the PMM2 promoter, as confirmed by our EMSA data (Figure 4). By 
simultaneously binding CTCF and the PMM2 promoter, ZNF143 could 
establish a functional chromatin loop enabling interaction between the 
promoter and a number of regulatory binding sites. This would allow specific 
spatiotemporal regulation of PMM2, depending on the expression profile of 
respective regulatory factors. While the expression of all genes contained in 
the chromatin loop could be affected by the promoter mutation, the fact that it 
is found in trans with coding mutations in PMM2 clearly implicate specific 
impairment of PMM2 regulation as the key disease mechanism in HIPKD. 
While other genes in the loop and especially TMEM167, which is regulated by 
the same promoter as PMM2 may also be affected, this effect is expected to 
be the same as in the asymptomatic heterozygous carriers of the promoter 
mutation without a PMM2 coding mutation in trans. The key role of PMM2 is 
further supported by the decreased PMM2 expression with the promoter 
mutation (Figure 4). Although PMM2 is expressed ubiquitously, there is 
evidence for additional tissue-specific regulation.22 A potential candidate 
involved in such tissue-specific regulation is the transcription factor HNF4A, 
which is expressed predominantly in the three organ systems involved in 
HIPKD: liver, pancreas and kidney.23 Indeed, we previously linked mutations in 
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HNF4A with HI and kidney disease.24 Clusters of HNF4A binding site are 
present in the loop (Supplemental Figures 2 and 3). HNF4A could affect PMM2 
transcription either positively in the setting of the wild type promoter, as it 
would require binding of ZNF143 to establish the functional loop; or negatively, 
by destabilizing a weakened interaction between mutant PMM2 promoter and 
ZNF143/CTCF. Under both scenarios, there would be decreased PMM2 
transcription from the mutant promoter in HNF4A expressing cells, compatible 
with tissue specific disease as seen in HIPKD. 
 
HIPKD and glycosylation 
Defective glycosylation has been previously linked to the development 
of HI or cystic kidney disease and both phenotypes have been described as 
part of the spectrum of clinical manifestations in the multivisceral form of 
CDG1A.25-29 Yet, given the predominance of neurological problems, only few 
data on the renal involvement in CDG1A are available, mainly that cysts can 
be seen on imaging, which on antenatal ultrasound may manifest as increased 
echogenicity (“antenatal bright kidneys”) and in cases with post mortem 
examination tubular microcysts were noted.25, 29, 30 Interestingly, the latter is 
different to the only available histology in our HIPKD cohort, which shows 
predominantly, if not exclusively, glomerular cysts (Figure 2).  
The consequences of impaired glycosylation for cystogenesis is evident 
from the recent identification of mutations in GANAB as a cause of kidney and 
liver cysts.31 Several animal studies provide further links: Mice deleted for 
Aqp11 develop cystic kidney disease due to altered glycosylation of 
polycystin132 and defective glycosylation of polycystin2 leads to cyst 
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formation.33 Thus, impaired glycosylation of key proteins involved in cystic 
kidney disease may be responsible for the development of renal cysts in 
HIPKD. There is also evidence for the importance of glycosylation for targeted 
membrane trafficking of the sulfonyl urea receptor (SUR), a key protein for 
regulated insulin secretion.34 This complements our own data, showing altered 
insulin secretion after deglycosylation (Figure 4E). Similarly, polycystic liver 
disease is associated with mutations in genes that cause abnormal 
glycosylation or processing of glycoproteins.35 
 
Conclusion 
In conclusion, we report a previously undescribed disease with the key 
manifestations of hyperinsulinemic hypoglycemia and polycystic kidney 
disease. All patients share a non-coding mutation, which disrupts binding of the 
transcription factor ZNF143 and impairs specific regulation of PMM2 
expression. Our findings are consistent with a critical role of protein 
glycosylation for normal insulin secretion and kidney morphology.  Selective 
organ involvement, as seen in the patients presented here, has to our 
knowledge not previously been associated with a promoter mutation and thus 
provides important insight into gene regulation. Identification of a disease-
causing promoter mutation emphasizes the importance of assessing non-
coding variants in the genetic analysis of disease.  
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Concise Methods 
Full details of all methods can be found in the Supplemental Methods. 
 
Genetic studies 
All subjects and/or their parents gave informed consent for genetic testing and 
all studies were approved by the respective institutional research ethics review 
boards.  Linkage analysis was performed as detailed previously.36  
Next generation sequencing was performed through Perkin Elmer 
(www.perkinelmer.com) and Illumina (www.illumina.com). Sequencing data 
were analyzed with an in-house pipeline, as well as Ingenuity variant analysis 
software (www.ingenuity.com). Identified mutations in PMM2 were confirmed 
with Sanger sequencing. 
 
EMSA  
EMSA was performed as described.37 ZNF143 was expressed in vitro and 
bound to biotinylated probes specific for either wild type or mutant promoter. 
Specificity was assessed by competition with excess of unlabeled probes. 
 
 
Insulin secretion 
Insulin-secreting MIN6 cells were maintained and insulin secretion measured 
as described previously.38, 39 To assess the effect of deglycosylation, the cells 
were incubated in the absence or presence of Peptide N-Glycosidase F and 
Endoglycosidase H. 
 
Luciferase assay 
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Promoter activity was assessed by placing 3 different promoter constructs 5’ to 
the renilla luciferase gene: 1) wild type, 2) c.-167G>T and 3) c.-180_-163del, 
the latter deleting the entire predicted ZNF143 binding site.7 
 
 
Digital PCR 
Analysis of allele-specific PMM2 expression was performed in primary renal 
cells from patient 6.1 obtained after nephrectomy. Cells were prepared and 
cultured as described previously.40 RNA was isolated and cDNA generated as 
described and used as template for digital PCR with primers specific for the 
alleles containing either the promoter or missense mutation.41  
 
Bioinformatics 
The genomic region around the PMM2 promoter was assessed for 
chromosomal segmentation, transcription factor and CTCF binding sites using 
the UCSC Human Genome browser with publicly available tracks. Chromatin 
loop formation was assessed using available Hi-C data.42 
 
Statistics 
Appropriate statistical assays were used as indicated in Supplemental Methods 
for the respective experimental data. A p<0.05 was considered significant. 
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Table 1 
 
Clinical Details 
Shown are pertinent clinical data for the 17 patients. Note the presence of the 
PMM2 promoter mutation c.-167G>T in all patients. 
 
N/A not available; * Ultrasound imaging of the liver was normal, yet a biopsy 
revealed ductal plate malformation (see Figure 3). 
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Figure 1 
Genetic studies 
A-E) Pedigrees of informative families used for linkage analysis. 
F) The combined parametric multipoint linkage analysis reveals a single 
significant peak with a maximum LOD score of 6.5 on chromosome 16. 
G) Sequencing of the linked region reveals the presence of the mutation 
c.-167G>T in the promoter of PMM2 in all patients. Shown are 
electropherogram traces of the region c.-173_–c.161 from a patient 
homozygous for the mutation, a control (wild type) subject, and a heterozygote 
parent. 
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Figure 2: 
Renal imaging and histology in children with hyperinsulinism and 
polycystic kidney disease (HIPKD) 
 
A) Ultrasound images of the kidney from patient 2.1, left kidney, age 11 years; 
B) patient 2.2, right kidney, age 4 years; and C) patient 6.1, right kidney, age 2 
years. Note the presence of cysts of various sizes. Kidney length was >95th 
percentile for age in all patients. 
D) Axial MRI image of the kidney from patient 2.1, age 11 years; E, F) Axial 
and coronal MRI images (without contrast) from patient 6.1, age 2 years. Note 
the massively enlarged kidneys with cysts of various sizes. 
G) Macroscopic appearance of the nephrectomy specimen from patient 6.1, 
age 2 years, removed at the time of transplant. Note the large kidney size (20 
cm longitudinal, normal < 7.7 cm) and numerous macroscopic cysts.  
H, I) Histology of the same kidney demonstrating multiple cysts lined by simple 
attenuated epithelium, with glomeruli noted in some (glomerulocystic disease; 
Hematoxylin and Eosin; original magnifications x20 and x100, respectively). 
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Figure 3 
Liver involvement in HIPKD 
A) Shown is an axial T2-weighted (STIR sequence) MRI image of patient 2.1 
showing numerous small liver cysts. B) Ultrasound image of the liver of patient 
2.2 showing a cyst. C, D) Photomicrographs of the liver biopsy from patient 
8.1. demonstrating abnormal and expanded portal tracts consistent with ductal 
plate malformation (Hematoxylin and Eosin; original magnifications x40 and 
x100, respectively). 
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Figure 4 
The c.-167G>T mutation impairs promoter function 
Luciferase activity is significantly reduced with mutant compared to wild type 
promoter in A) human pancreatic β-cell line 1.1B4 and B) human kidney cell 
line RPTEC/TERT1. Light gray bars show luciferase activity with wild type 
promoter, black bars with the c.-167G>T mutation and the cross-hatched bars 
show activity with deletion of the ZNF143 binding site c.-163_-180del. Asterisk 
indicates significance (wild type versus respective mutation; p<0.01). 
C) In kidney cells derived from patient 6.1 expression of the allele with the 
mutant promoter (c.-167G>T) is significantly reduced compared to the other 
allele. Asterisk indicates significance (p<0.01). 
D) Electrophoretic mobility shift assay (EMSA) demonstrating reduced affinity 
of mutant promoter to ZNF143. Note the impaired binding of ZNF143 (indicated 
by arrow) to the mutant (lane 3) compared to wild type (lane 1) PMM2 
promoter. Binding is specific, as addition of excess unlabeled wild type (lane 2) 
or mutant promoter probe (lane 4) abolishes binding to the labeled probes. 
Moreover, no specific binding is seen in the negative control (no ZNF143) to 
either wild type (lane 5) or mutant (lane 6) promoter probe.  
E) Densitometry confirms significantly reduced affinity of ZNF143 to mutant 
promoter (P<0.01). Bands from lane 1 and 3 indicated by arrow in D) were 
measured by densitometry and results pooled from 5 independent 
experiments. 
F) Deglycosylation alters insulin secretion in a murine pancreatic β-cell line 
(MIN6). There is significant increase in insulin secretion after stimulation with 
high glucose (p<0.01), as expected. Note the significant (p<0.01) increase in 
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insulin secretion with deglycosylation after further stimulation with phorbol-12 
myristate-13 acetate (PMA). 
 
 
 
